Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee , Dow Street, Dundee, DD1 5EH, Scotland, U.K.
J Med Chem. 2018 Jan 25;61(2):504-513. doi: 10.1021/acs.jmedchem.6b01912. Epub 2017 Jun 22.
The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-molecule approach for inducing protein degradation. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. Here we examined the impact of derivatizing two different BET bromodomain inhibitors, triazolodiazepine JQ1 and the more potent tetrahydroquinoline I-BET726, via distinct exit vectors, using different polyethylene glycol linkers to VHL ligand VH032. Triazolodiazepine PROTACs exhibited positive cooperativities of ternary complex formation and were more potent degraders than tetrahydroquinoline compounds, which showed negative cooperativities instead. Marked dependency on linker length was observed for BET-degrading and cMyc-driven antiproliferative activities in acute myeloid leukemia cell lines. This work exemplifies as a cautionary tale how a more potent inhibitor does not necessarily generate more potent PROTACs and underscores the key roles played by the conjugation. The provided insights and framework for structure-activity relationships of bivalent degraders are anticipated to have wide future applicability.
蛋白水解靶向嵌合体(PROTACs)的设计是一种诱导蛋白质降解的有效小分子方法。PROTACs 通过连接子将靶弹头与 E3 泛素连接酶配体连接起来。在这里,我们通过不同的聚乙二醇接头将两种不同的 BET 溴结构域抑制剂,三唑并哒嗪 JQ1 和效力更强的四氢喹啉 I-BET726,衍生为不同的出口载体,用于 VHL 配体 VH032。三唑并哒嗪 PROTACs 表现出三元复合物形成的正协同性,并且比四氢喹啉化合物更有效,后者则表现出负协同性。在急性髓系白血病细胞系中,BET 降解和 cMyc 驱动的抗增殖活性与接头长度有明显的依赖性。这项工作说明了一个警示故事,即更有效的抑制剂不一定会产生更有效的 PROTACs,并强调了连接在其中发挥的关键作用。预计所提供的双价降解物的结构-活性关系的见解和框架将具有广泛的未来适用性。